Curated News
By: NewsRamp Editorial Staff
September 29, 2026
NanoViricides Advances NV-387 with Phase II Trials for Mpox and Ebola
TLDR
- NanoViricides gained DRC approval for Phase II NV-387 trials and FDA designations for measles, advancing its antiviral pipeline ahead of rivals.
- NanoViricides received DRC approval for Phase II trials of NV-387 Oral Gummies for Mpox and Ebola, beginning enrollment in September 2026.
- NanoViricides' NV-387 could treat Mpox, Ebola, and measles, offering hope for better global health outcomes and saving lives.
- NanoViricides' NV-387 is a broad-spectrum antiviral in oral gummy form, now in Phase II trials for Mpox and Ebola in the DRC.
Impact - Why it Matters
This news matters because it signals a potential breakthrough in the fight against highly infectious and often deadly diseases like Mpox, Ebola, and measles. The approval to begin Phase II trials in the Democratic Republic of Congo—a region frequently affected by outbreaks—demonstrates that NanoViricides' broad-spectrum antiviral platform is moving closer to providing a much-needed therapeutic option. If successful, NV-387 could offer a single treatment for multiple viral threats, simplifying response efforts during outbreaks and reducing the burden on healthcare systems. Moreover, the FDA designations for measles highlight the drug's potential to address a resurgence of a disease once thought eliminated in many parts of the world. For investors, the progress and additional funding indicate growing confidence in the company's pipeline, but as with all drug development, significant risks and lengthy timelines remain. The outcomes of these trials could have far-reaching implications for global health security and antiviral innovation.
Summary
NanoViricides, Inc. (NYSE American: NNVC) has announced significant progress in its antiviral development efforts, reporting fiscal year 2026 results that highlight regulatory and clinical milestones for its lead broad-spectrum antiviral candidate, NV-387. The company received regulatory approval in the Democratic Republic of Congo to initiate Phase II trials evaluating NV-387 Oral Gummies for the treatment of Mpox and Ebola, with both trials beginning enrollment at the end of September 2026. Additionally, NanoViricides secured U.S. Food and Drug Administration Orphan Drug Designation and Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles, underscoring the drug's potential to address serious unmet medical needs.
Financially, NanoViricides reported approximately $2.79 million in cash and cash equivalents as of June 30, compared with approximately $1.67 million a year earlier, and raised approximately $9.01 million through registered direct and at-the-market equity offerings during fiscal 2026. The company subsequently raised approximately $3.8 million in July and said it is pursuing additional funding through grants and contracts, partnerships, debt or equity financing. To view the full press release, visit https://ibn.fm/s000r.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide(TM) class of drug candidates and technology are based on intellectual property from TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. Other advanced candidates include NV-HHV-1 for Shingles. NanoViricides is focused on advancing NV-387 into Phase II human clinical trials. For more information, visit www.nanoviricides.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances NV-387 with Phase II Trials for Mpox and Ebola
